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Spectrum of pncA Mutations in Multidrug-Resistant
Mycobacterium tuberculosis Isolates
Obtained in Latvia
Pyrazinamide (PZA) is an effective antituberculous agent
(1) that becomes active when bacterial pyrazinamidase con-
verts it to pyrazinoic acid, which is toxic to mycobacteria (4). In
Mycobacerium tuberculosis, PZA resistance is associated with
the loss of pyrazinamidase activity, mainly due to mutations in
the pncA gene coding region or in the putative regulatory area
upstream of it (7, 9).
The molecular basis of resistance to PZA in M. tuberculosis
has been extensively studied in recent years. Nevertheless,
more studies should be done in order to evaluate molecular
methods for PZA susceptibility testing, which is complicated
(10). For that purpose, we examined the pncA gene in 28
randomly selected PZA-resistant and 10 randomly selected
PZA-susceptible single-culture isolates of multidrug-resistant
(MDR) M. tuberculosis from 38 patients in Latvia, where a high
MDR level persists (12). Cultures were collected in the State
Centre of Tuberculosis and Lung Diseases between 2001 and
2002; they represented about 10% of all MDR cultures iso-
lated annually. All 38 cultures were resistant to rifampin, iso-
niazid, and streptomycin. Drug susceptibility was determined
by the BACTEC method (Becton Dickinson, Sparks, Md.) (3).
Native DNA was isolated as previously described (13). To
amplify the 720-bp fragment containing the 561-bp pncA gene
and the surrounding regions, the P1–P6 primer set and Taq
DNA polymerase (MBI Fermentas, Vilnius, Lithuania) were
used (10). PCR products were analyzed by automatic nucleo-
tide sequencing of both DNA chains by using the ABI
PRISM 3100 DNA analyzer (Applied Biosystems, Inc., Fos-
ter City, Calif.).
Results from sequencing of the 28 PZA-resistant MDR M.
tuberculosis isolates are shown in Table 1. Altogether, point
mutations were found in 23 (82%) of the 28 PZA-resistant
isolates and were located in 10 different codons of the pncA
gene, leading to amino acid changes. One mutation resulted in
premature termination of synthesis. Codons T76 and Y103
were most frequently affected (43%). One isolate showed a
mixture of the wild-type and mutant sequences, with mutations
at codons C14 and Y103, which arose independently, as this
isolate had a unique pattern (data not shown). Five isolates
showed the wild-type pncA gene sequence, indicating an alter-
native mechanism for PZA resistance. No mutations were
found in the PZA-susceptible MDR isolates.
We have detected mutations at three novel codons, C14Y,
D63G, and V180F, by sequencing of both DNA strands from
two independent PCRs; the remaining seven mutated codons
have been described previously (2, 5–8, 10, 11). Here, muta-
tions occurred most frequently in codons T76 and Y103 but
were not found in codons R140, L85, and T47, reported pre-
viously (2, 5–8, 10, 11). Seven of 10 mutated codons (Q10, C14,
P62, D63, C72, T76, and C138) were located in the three “hot”
regions of the pncA gene as suggested by Scorpio et al. (10),
partially confirming their hypothesis.
The relatively high percentage of mutations found in the
pncA gene by sequencing should contribute to its further use
for PZA susceptibility testing. However, it should be kept in
mind that 18% of PZA-resistant isolates had no pncA muta-
tions.
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Nucleotide sequencea Amino acidb
5 (18) A3C at position 226 T763P
5 (18) T3C at position 307 Y1033H
2 A3G at position 188 D633G
2 C3D at position 216 C723W
2 T3G at position 254 L853R
1 C3T at position 28 Q103Ter
1 G3A at position 41 C143Y
1 C3A at position 184 P623T
1 A3T at position 308 Y1033S
1 G3A at position 413 C1383Y
1 G3T at position 537 V1803F
1 WT/C3G at position 42 
T3C at position 307
WT/C143W  Y1033H
5 (18) WT WT
a WT, wild type.
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